Federated Hermes’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,232,546
| Closed | -$47.4M | – | 2260 |
|
|
2023
Q2 | $47.4M | Sell |
1,232,546
-19,842
| -2% | -$510K | 0.12% | 217 |
|
|
2023
Q1 | $29M | Buy |
1,252,388
+363,934
| +41% | +$8.68M | 0.07% | 305 |
|
|
2022
Q4 | $23.3M | Buy |
888,454
+750,191
| +543% | +$16.6M | 0.06% | 347 |
|
|
2022
Q3 | $2.72M | Buy |
+138,263
| New | +$2.77M | 0.01% | 827 |
|
|
2021
Q2 | – | Sell |
-18,099
| Closed | -$282K | – | 2367 |
|
|
2021
Q1 | $282K | Buy |
18,099
+16,378
| +952% | +$267K | ﹤0.01% | 1654 |
|
|
2020
Q4 | $27K | Buy |
+1,721
| New | +$26K | ﹤0.01% | 1889 |
|
|
2020
Q2 | – | Sell |
-123
| Closed | -$2K | – | 2410 |
|
|
2020
Q1 | $2K | Buy |
+123
| New | +$1.45K | ﹤0.01% | 2053 |
|
|
2018
Q4 | – | Sell |
-2,066
| Closed | -$76K | – | 2345 |
|
|
2018
Q3 | $76K | Buy |
2,066
+1,505
| +268% | +$48.3K | ﹤0.01% | 1696 |
|
|
2018
Q2 | $20K | Buy |
561
+75
| +15% | +$2.88K | ﹤0.01% | 1802 |
|
|
2018
Q1 | $23K | Buy |
486
+25
| +5% | +$915 | ﹤0.01% | 1741 |
|
|
2017
Q4 | $17K | Buy |
461
+69
| +18% | +$3.01K | ﹤0.01% | 1803 |
|
|
2017
Q3 | $21K | Buy |
392
+41
| +12% | +$2.44K | ﹤0.01% | 1751 |
|
|
2017
Q2 | $20K | Buy |
351
+40
| +13% | +$2.01K | ﹤0.01% | 1764 |
|
|
2017
Q1 | $17K | Buy |
+311
| New | +$17.6K | ﹤0.01% | 1760 |
|
Federated Hermes's KDNY Position: Q3 2023 in Review
Federated Hermes sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,232,546 shares — an estimated $47.4M sold.
Federated Hermes first reported a position in KDNY in Q1 2017 and held it in 14 quarters. The position peaked at $47.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Federated Hermes reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Federated Hermes sold 1,232,546 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $47.4M.
- Federated Hermes first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 14 quarters.
- Federated Hermes's Chinook Therapeutics, Inc. Common Stock position peaked at $47.4M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.